SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MJ who wrote (1107)10/11/1998 3:51:00 PM
From: John S. Baker  Read Replies (1) of 1510
 
"Is it possible that the IMNR treatment for AIDS could be the opening of the door for treating other viruses in a similar fashion. Or even a bridge to treating other diseases whose end results are similar in nature---i.e. the breakdown of the autoimmune system."

I am not a medical expert ... just a long-term IMNR shareholder ... but a recent company presentation leads me to believe that the key element is the company's approach (my word).

This approach might be expected to be effective in many other areas of study.

----

I don't know enough about the origin of AIDS to respond to your other question ... except to note that people rarely died of cancer 100 years ago. They usually died of something else first.

Genetics can be a strange thing.

JSb.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News